Kenny Walter is an editor with HCPLive. Prior to joining MJH Life Sciences in 2019, he worked as a digital reporter covering nanotechnology, life sciences, material science and more with R&D Magazine. He graduated with a degree in journalism from Temple University in 2008 and began his career as a local reporter for a chain of weekly newspapers based on the Jersey shore. When not working, he enjoys going to the beach and enjoying the shore in the summer and watching North Carolina Tar Heel basketball in the winter.
The treatment improves morning function for adolescent ADHD patients.
Methylphenidate could be a crucial treatment for adolescent patients with attention deficit/hyperactivity disorder (ADHD) in a delayed-release and extended-release formulation.
In research presented during the American Professional Society of ADHD and Related Disorders (APSARD) 2021 Annual Conference a team of investigators presented new data showing the treatment resulted in improvements in ADHD symptoms and early morning functional impairment for children between 6-12 years old with the disorder.
The researchers tested the treatment in a 20 or 40 mg per dose phase 3 trial involving 125 adolescent patients with a mean age of 9.4 years.
Over the course of the 6 week study, mean ADHD-Rating Scale-IV scores decreased from 42.5 at baseline to 11.00 at week 6, while Before School Functioning Questionnaire (BSFQ) scores improved after 1 week of treatment.
The researchers also found that the proportion of patients who achieved symptomatic and early morning functional impairment response and remission thresholds increased after each week of treatment.
When doses were titrated weekly, with the aim of control throughout the day, most patients achieved response and remission thresholds, with early morning and late afternoon/evening functional impairment found at the end of the six-week, treatment optimization period.
In an interview with HCPLive®, Andrew J. Cutler, MD, Clinical Professor of Psychiatry at SUNY Upstate Medical University, explained the positive results presented at APSARD.